首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備包裝/容器

市場調查報告書

商品編碼

1410087

2023年至2028年非PVC輸液袋市場預測

Non-PVC IV Bags Market - Forecasts from 2023 to 2028

出版日期: 2023年12月12日 | 出版商:

Knowledge Sourcing Intelligence | 英文 141 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

2021年全球非PVC輸液袋市場規模為11.49億美元。

預計非 PVC IV 袋市場將在整個預測期內穩定成長。由聚氯乙烯 (PVC) 以外的材料製造的輸液袋稱為非 PVC 輸液袋。非 PVC 輸液袋通常由對人體風險較低的材料製成，例如聚烯烴、聚氨酯和磺酸鹽。非PVC輸液袋市場是由癌症患者和腎衰竭等慢性疾病數量的增加所推動的。

癌症患者增加

非PVC輸液袋市場受到人口中癌症患者數量不斷增加以及對癌症治療過程（尤其是化療和標靶藥物輸送）快速成長的需求的影響。例如，2020 年，六分之一的死亡者，約 1000 萬人，死於癌症，根據世界衛生組織的數據，癌症是全球死亡的主要原因。據估計，低收入和中等收入國家 30% 的癌症病例是由人類乳突病毒 (HPV) 和肝炎等致癌感染疾病引起的。非 PVC 輸液袋可以安全使用，因為它們造成的污染危害較小。

慢性病增加

需要透析的腎衰竭等慢性疾病的增加預計將在未來幾年推動非 PVC IV 袋市場的發展。例如，美國有 3700 萬成年人患有慢性腎臟病(CKD)，即超過七分之一的人患有慢性腎臟病。對於患有腎臟疾病的兩個主要原因之一（糖尿病或高血壓）的美國來說，慢性腎臟病的風險甚至更高。此外，根據世界衛生組織 (WHO) 2022 年更新，慢性阻塞性肺病(COPD) 是全球第三大死因，低收入和中等收入(LMIC) 國家每年約有90 人死於15 歲以下的疾病. 70% 的人死亡。由於接受心臟心血管手術或接受急性加重治療的患者對用於靜脈輸液的非 PVC IV 袋的需求預計會增加，預計該市場將會開拓。

政府努力增加非 PC IV 袋的使用

有關 PVC 使用和處置的嚴格規定以及新興國家醫療基礎設施的改善也推動了非 PVC 輸液袋市場的發展。歐洲、美國、加拿大和日本的多個政府機構和專家小組已確定，使患者接觸 DEHP 的醫療程序可能會對患者造成健康風險。例如，為了保護早產兒和新生兒，德國聯邦藥品和醫療設備研究所 (BfArM)建議不要使用由 DEHP 軟化 PVC 製成的醫療設備。此外，BfArM 呼籲醫療設備製造商揭露其產品含有 DEHP，並投入時間和精力來創造更安全的替代品。

市場機會

預計上述成長要素將為非 PVC IV 袋市場的擴張提供重大機會。除了這些因素之外，患者對塑膠袋有害影響的認知不斷提高，進一步顯示非 PVC 輸液袋市場的成長。 PVC材料常用於包裝。然而，由於它們無法分解，它們的處置會對環境產生負面影響。日益嚴重的環境問題導致了 PVC 環保替代品的開發，這推動了全球非 PVC IV 袋市場的擴張。例如，為了促進整個歐洲醫療保健的永續性，VinylPlus Med 於 2021 年 10 月在比利時正式啟動了醫用 PVC 回收試點計畫。該計劃回收廢棄的一次性 PVC醫療設備，包括氧氣罩面罩、麻醉面罩、管道、靜脈滴注和透析袋。

市場抑制因素

預計很少有因素會限制非 PVC IV 袋市場的成長。在輸注藥物水溶液過程中，從 PVC 管中洗脫出來的 DEHP 分子會對健康產生許多不利影響，包括但不限於人類代謝紊亂。此外，非 PVC 輸液器不含 DEHP 分子，可能會導致不良的健康影響。

北美地區預計將大幅成長

在預測期內，北美地區預計將佔據非 PVC IV 袋市場的主要佔有率。造成這一比例的因素包括癌症患者數量的增加、對 PVC IV 袋有害影響的認知以及嚴格的政府法規。例如，根據美國癌症協會的數據，預計 2023 年美國將診斷出約 190 萬例新癌症病例。根據 FDA 安全評估和公共衛生通告，美國食品藥物管理局建議某些易感族群使用含 DEHP 裝置的替代品。此外，Baxter 和 ICU Medical 等市場領導的出現預計將進一步推動該地區的非 PVC IV 袋市場。

主要市場參與者

百特透過急診、營養、腎臟病和外科護理產品改善世界各地的醫療保健。我們提供200 多種輸液治療，包括Viflex 和Viaflo 容器中的0.9% 氯化鈉注射液（非PVC）、注射用葡萄糖、乳酸林格氏液和林格氏液、奧米特羅、等離子光、無菌水、葡萄糖用氯化鉀和鈉注射液提供有效代碼。我們也為藥物重組系統提供輸液解決方案。 ICU Medical 是一家總部位於美國的醫療公司，專門從事靜脈治療。該公司的輸液配方在美國的美國工廠生產，只需一到兩天即可可靠交付。該公司提供 Supercath 5 IV 導管、Y 型連接器、帶 Clave(TM) 的小瓶適配器、雙母頭連接器、Supercath 5 IV 導管等。

市場主要發展

2022 年 6 月，Gufic Biosciences 在印度推出了帶有可剝離鋁箔的聚丙烯（不含 DEHP）雙腔室袋。這些袋子可以就地儲存需要在給藥前立即重新配製的不穩定藥物。這是一種全新的藥物傳輸技術，印度希望將其本土化。 2021 年 9 月，B.Braun 首次在美國市場推出了可選 AirStop 的非 PVC IV 套裝 CARESAFE IV 管理套裝。由於它只允許液體通過，因此可以防止管路乾燥。 2020年11月，Fagron Stellail Services推出了一個名為靜脈（IV）袋的新產品平台，以在2021年繼續擴展產品系列。該公司承諾 98% 的準時交貨率和供應協議，提供單獨包裝的產品，以延長保存期限並保護產品。

The non-PVC IV bags market is anticipated to grow at a steady pace throughout the forecast period. Intravenous bags produced from substances other than polyvinyl chloride (PVC) are known as non-PVC IV bags. Non-PVC IV bags are often created from substances that are less dangerous to human health, such as polyolefins, polyurethane, and polyethersulfone. The rising number of cancer cases and other chronic diseases such as kidney failure are major factors in the non-PVC IV bags market as the therapy in the treatments in these conditions requires IV bags.

Rising Cancer Cases

The non-PVC IV bags market is impacted by the growth in cancer cases in the population as well as the surge in demand for oncology processes, particularly for chemotherapy and targeted drug delivery. For instance, one in six deaths, or around 10 million deaths, was due to cancer in 2020, making it the top cause of death globally as per the WHO. In low and lower-middle-income nations, cancer-causing infections including the human papillomavirus (HPV) and hepatitis are estimated to be the cause of 30% of cancer cases. Non-PVC IV bags are less harmful concerning the contamination thus it is safe to use non-PVC IV bags.

Growing Burden of Chronic Diseases

The growing prevalence of chronic diseases such as kidney failure which require dialysis is expected to drive the non-PVC IV bags market in the coming years. For instance, in the United States, 37 million adults which is more than 1 in 7 have chronic kidney disease (CKD). The risk of CKD is even higher for Americans who have either diabetes or high blood pressure, the two main causes of kidney disease. Moreover, chronic obstructive pulmonary disease (COPD), the third highest cause of mortality globally, kills approximately 90% of those under the age of 70 in low- and middle-income (LMIC) countries, according to World Health Organisation (WHO) updates 2022. Due to the predicted rise in demand for non-PVC IV bags used to provide intravenous fluids to patients undergoing heart surgery and those being treated for acute exacerbations, the market is expected to develop.

Government Efforts to Increase the Use of Non-PC IV Bags

The non-PVC IV bags market is also being boosted by rigorous regulations governing the use and disposal of PVC and improved healthcare infrastructure in developing nations. It has been determined by several government agencies and expert panels in Europe, the US, Canada, and Japan that several medical treatments that expose patients to DEHP may be harmful to their health. For instance, to protect premature infants and newborns, the German Federal Institute for Drugs and Medical Equipment (BfArM) advises against using medical equipment made of DEHP-softened PVC. Additionally, BfArM asks producers of medical devices to disclose the presence of DEHP in their goods and to invest more time and energy in creating safer substitutes.

Opportunities in the Market

These growth factors mentioned above are predicted to provide an immense opportunity in the non-PVC IV bags market expansion. Apart from these factors, the growing awareness among patients about the harmful effects of plastic bags further indicates the growth in the non-PVC IV bags market. Packaging frequently uses PVC materials. However, because they cannot decompose, their disposal has a detrimental effect on the environment. Due to growing environmental concerns, eco-friendly PVC replacements are being developed, which is fueling the expansion of the non-PVC IV bag market globally. For instance, to advance sustainability in healthcare across Europe, VinylPlus Med officially inaugurated its pilot medical PVC recycling program in Belgium in October 2021. This program will recycle discarded single-use PVC medical devices, such as oxygen and anaesthetic masks, tubing, IVs, and dialysis bags.

Restraints in the Market

Few factors are expected to limit the non-PVC IV bags market growth. The leached DEHP molecules from the PVC tube during intravenous infusion of aqueous drug solutions produce many harmful health effects, including but not limited to a disruption in human metabolism. Additionally, non-PVC infusion sets do not carry the DEHP molecules, which causes unfavourable health effects.

North America is Expected to Grow Significantly

The North American region is supposed to hold a significant share of the non-PVC IV bags market during the forecast period. Various factors attributed to such a share are rising cancer cases, awareness about the hazardous effects of PVC IV bags, and stringent government regulations. For instance, around 1.9 million new cancer cases are anticipated to be diagnosed in 2023 in the US as per the American Cancer Society. Using alternatives to DEHP-containing devices for specific, susceptible individuals is advised by the US Food and Drug Administration, according to an FDA Safety Assessment and a Public Health Notification. Moreover, the presence of market leaders such as Baxter and ICU Medical is further predicted to propel the non-PVC IV bags market in the region.

Major Market Players

Baxter offers a range of acute, nutritional, renal, and surgical care products to advance healthcare around the globe. It offers more than 200 active codes for fluid therapy such as 0.9% sodium chloride injection in both Viflex and Viaflo containers (non-PVC), dextrose for injection, lactated ringers & ringers, OSMITROL, Plasmalyte, sterile water, and potassium chloride in dextrose & sodium injections. It also provides an IV solution for the drug reconstitution system.
ICU Medical, a US-based medical company focussed on IV therapy. Its IV solutions are produced in two US plants with reliable delivery in just one to two days in the US. It offers Supercath 5 IV Catheter, Y-Connector, Vial Adapter with Clave™, Double Female Connector, Supercath 5 IV Catheter, and others.

Key Market Developments

In June 2022, dual chamber IV bags made of polypropylene (DEHP free) with a peelable aluminium foil were introduced by Gufic Biosciences in India. These bags allow the storage of unstable medications that need to be reconstituted right before administration at the point. This is a brand-new medicine delivery technology that India intends to produce domestically.
In September 2021, B.Braun launched a non-PVC IV set, CARESAFE IV Administration Sets with optional AirStop to reduce patient exposures to toxic substances which was the first in the US market. It helps keep the line from drying out because it is made to only let fluid pass.
In November 2020, Fagron Sterile Services launched a new product platform named Intravenous (IV) Bags for the continued expansion of its product portfolio in 2021. It is committed to supply agreements offered with a 98% on-time delivery rate and products individually wrapped for extended beyond-use dating and product protection.

Segmentation:

By Product

Single Chamber
Multi-Chamber

By Material

Ethylene Vinyle Acetate
Polypropylene
Copolyester ether
Others

By Content

Frozen Mixture
Liquid Mixture

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. NON-PVC IV BAGS MARKET, BY PRODUCT

5.1. Introduction
5.2. Single Chamber
5.3. Multi Chamber

6. NON-PVC IV BAGS MARKET, BY MATERIAL

6.1. Introduction
6.2. Ethylene Vinyle Acetate
6.3. Polypropylene
6.4. Copolyester ether
6.5. Others

7. NON-PVC IV BAGS MARKET, BY CONTENT

7.1. Introduction
7.2. Frozen Mixture
7.3. Liquid Mixture

8. NON-PVC IV BAGS MARKET, BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Spain
- 8.4.5. Others
8.5. The Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Israel
- 8.5.4. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others